0
Startups & Venture·September 16, 2026·1 min read

Sources: Shanghai-based Anew Labs, a ByteDance spinoff using AI for drug discovery, raised $290M from HSG, IDG Capital, and others at a $1.5B valuation

Share

A $290M raise at a $1.5B valuation for an AI drug discovery spinout shows Big Tech is comfortable incubating deeptech and then capitalizing it like a biotech. Pharma and healthtech operators should assume China will field well-funded AI-native drug platforms competing globally on both speed and cost.

Startups & Venture

Source: AI assistant Instinct seeks to raise $1B at a $10B valuation, up from $2.25B less than a month ago; Sequoia and Benchmark are in talks to lead the round

A jump from $2.25B to $10B in under a month for a personal AI assistant is less about current revenue and more about locking up a perceived distribution wedge before the platform giants do. If you’re building in the assistant/agent space, assume capital will fund land-grabs around identity, memory, and OS integration, not incremental features.